Inflammation as a central mechanism in Alzheimer's disease Tập 4 Số 1 - Trang 575-590 - 2018
Jefferson W. Kinney, Shane M. Bemiller, Andrew S. Murtishaw, Amanda M. Leisgang, Arnold Salazar, Bruce T. Lamb
AbstractAlzheimer's disease (AD) is a progressive neurodegenerative disorder
that is characterized by cognitive decline and the presence of two core
pathologies, amyloid β plaques and neurofibrillary tangles. Over the last
decade, the presence of a sustained immune response in the brain has emerged as
a third core pathology in AD. The sustained activation of the brain's resident
macrophages (micro... hiện toàn bộ
Alzheimer's disease drug development pipeline: 2018 Tập 4 Số 1 - Trang 195-214 - 2018
Jeffrey L. Cummings, Garam Lee, Aaron Ritter, Kate Zhong
AbstractIntroductionTreatments for Alzheimer's disease (AD) are needed due to
the growing number of individuals with preclinical, prodromal, and dementia
forms of AD. Drug development for AD therapies can be examined by inspecting the
drug development pipeline as represented on
clinicaltrials.gov.MethodsClinicaltrials.gov was assessed as of January 30, 2018
to determine AD therapies represented in... hiện toàn bộ
Alzheimer's disease drug development pipeline: 2017 Tập 3 Số 3 - Trang 367-384 - 2017
Jeffrey L. Cummings, Garam Lee, Travis Mortsdorf, Aaron Ritter, Kate Zhong
AbstractIntroductionThere is an urgent need to develop new treatments for
Alzheimer's disease (AD) and to understand the drug development process for new
AD therapies.MethodsWe assessed the agents in the AD pipeline as documented in
clinicaltrials.gov for phase I, phase II, and phase III, accessed
1/5/2017.ResultsThere are 105 agents in the AD treatment development pipeline,
of which 25 agents are... hiện toàn bộ
Sedentary behavior as a risk factor for cognitive decline? A focus on the influence of glycemic control in brain health Tập 3 Số 3 - Trang 291-300 - 2017
Michael J. Wheeler, Paddy C. Dempsey, Megan S. Grace, Kathryn A. Ellis, Paul A. Gardiner, Daniel J. Green, David W. Dunstan
AbstractCognitive decline leading to dementia represents a global health burden.
In the absence of targeted pharmacotherapy, lifestyle approaches remain the best
option for slowing the onset of dementia. However, older adults spend very
little time doing moderate to vigorous exercise and spend a majority of time in
sedentary behavior. Sedentary behavior has been linked to poor glycemic control
and... hiện toàn bộ
Amyloid‐associated increases in longitudinal report of subjective cognitive complaints Tập 4 - Trang 444-449 - 2018
Rebecca E. Amariglio, Rachel F. Buckley, Elizabeth C. Mormino, Gad A. Marshall, Keith A. Johnson, Dorene M. Rentz, Reisa A. Sperling
AbstractIntroductionTo investigate whether baseline subjective cognitive
complaints (SCCs) predict longitudinal decline on neuropsychological testing and
whether SCC increases longitudinally, in the setting of high levels of amyloid
burden.MethodsTwo hundred seventy‐nine clinically normal older participants
(mean age = 73.7 ± 6.1 years) from the Harvard Aging Brain Study, a cohort of
community‐dwe... hiện toàn bộ
Accelerating drug development for Alzheimer's disease through the use of data standards Tập 3 - Trang 273-283 - 2017
Jon Neville, Steve Kopko, Klaus Romero, Brian Corrigan, Bob Stafford, Elizabeth LeRoy, Steve Broadbent, Martin Cisneroz, Ethan Wilson, Eric Reiman, Hugo Vanderstichele, Stephen P. Arnerić, Diane Stephenson
AbstractIntroductionThe exceedingly high rate of failed trials in Alzheimer's
disease (AD) calls for immediate attention to improve efficiencies and learning
from past, ongoing, and future trials. Accurate, highly rigorous standardized
data are at the core of meaningful scientific research. Data standards allow for
proper integration of clinical data sets and represent the essential foundation
for... hiện toàn bộ
Online study partner‐reported cognitive decline in the Brain Health Registry Tập 4 - Trang 565-574 - 2018
Rachel L. Nosheny, Monica R. Camacho, Philip S. Insel, Derek Flenniken, Juliet Fockler, Diana Truran, Shannon Finley, Aaron Ulbricht, Paul Maruff, Kristine Yaffe, R. Scott Mackin, Michael W. Weiner
AbstractIntroductionMethods for efficiently identifying cognitive decline and
Alzheimer's disease (AD) are a critical unmet need. The goal of this work was to
validate novel online study partner (SP)‐reported outcomes to identify cognitive
decline in older adults.MethodsIn older adults enrolled in the Brain Health
Registry, we analyzed associations between SP‐reported cognitive decline,
measured b... hiện toàn bộ
Neural correlates of episodic memory in the Memento cohort Tập 4 - Trang 224-233 - 2018
Stephane Epelbaum, Vincent Bouteloup, Jean F. Mangin, Valentina La Corte, Raffaela Migliaccio, Hugo Bertin, Marie O. Habert, Clara Fischer, Chabha Azouani, Ludovic Fillon, Marie Chupin, Bruno Vellas, Florence Pasquier, Jean F. Dartigues, Fréderic Blanc, Audrey Gabelle, Mathieu Ceccaldi, Pierre Krolak-Salmon, Jacques Hugon, Olivier Hanon
AbstractIntroductionThe free and cued selective reminding test is used to
identify memory deficits in mild cognitive impairment and demented patients. It
allows assessing three processes: encoding, storage, and recollection of verbal
episodic memory.MethodsWe investigated the neural correlates of these three
memory processes in a large cohort study. The Memento cohort enrolled 2323
outpatients pre... hiện toàn bộ
Biomedical informatics applications for precision management of neurodegenerative diseases Tập 4 - Trang 357-365 - 2018
Justin B. Miller, Guogen Shan, Joseph Lombardo, Gustavo Jimenez-Maggoria
AbstractModern medicine is in the midst of a revolution driven by “big data,”
rapidly advancing computing power, and broader integration of technology into
healthcare. Highly detailed and individualized profiles of both health and
disease states are now possible, including biomarkers, genomic profiles,
cognitive and behavioral phenotypes, high‐frequency assessments, and medical
imaging. Although t... hiện toàn bộ
Cerebrospinal fluid neurogranin/β‐site APP‐cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease Tập 4 - Trang 617-627 - 2018
Bjørn-Eivind Kirsebom, Kaja Nordengen, Per Selnes, Knut Waterloo, Silje Bøen Torsetnes, Berglind Gísladóttir, Britta Brix, Eugeen Vanmechelen, Geir Bråthen, Erik Hessen, Dag Aarsland, Tormod Fladby
AbstractIntroductionThe cerebrospinal fluid neurogranin (Ng)/β‐site amyloid
precursor protein‐cleaving enzyme 1 (BACE1) ratio may reflect synaptic affection
resulting from reduced beta‐amyloid (Aβ) clearance. We hypothesize that
increased Ng/BACE1 ratio predicts the earliest cognitive decline in Alzheimer's
disease.MethodsWe compared Ng/BACE1 levels between cases with subjective
cognitive decline ... hiện toàn bộ